SCHEMBL6435699

SCHEMBL6435699

O=C(O)c1cc2cc(OCC3CCOCC3)ccc2[nH]1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.56
ALDH1A1 P00352 2/20 0.56
HPGD P15428 2/20 0.56
HSD17B10 Q99714 2/20 0.56
CYP1A2 P05177 1/20 0.56
CYP2C9 P11712 1/20 0.56
SRD5A2 P31213 1/20 0.56
ITGB3 P05106 3/20 0.56
ITGA2B P08514 3/20 0.56
KMT2A Q03164 1/20 0.51
PDGFRB P09619 3/20 0.47
PDGFRA P16234 3/20 0.47
HRH3 Q9Y5N1 4/20 0.46
PLA2G4A P47712 1/20 0.46
FGFR1 P11362 1/20 0.45
FGFR2 P21802 1/20 0.45
FGFR3 P22607 1/20 0.45
SMAD3 P84022 1/20 0.45
F7 P08709 1/20 0.44
F3 P13726 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18114411 0.91 KDM4E (0.62) KDM4EALDH1A1HPGDHSD17B10CYP1A2
SCHEMBL6418981 0.89 ITGB3 (0.53) KDM4EALDH1A1HPGDHSD17B10CYP1A2
SCHEMBL6418974 0.89 ITGB3 (0.53) KDM4EALDH1A1HPGDHSD17B10CYP1A2
SCHEMBL19885733 0.88 KDM4E (0.58) KDM4EALDH1A1HPGDHSD17B10CYP1A2
SCHEMBL6437692 0.86 ITGB3 (0.52) KDM4EALDH1A1HPGDHSD17B10CYP1A2
SCHEMBL13596586 0.84 ITGB3 (0.54) KDM4EALDH1A1HPGDHSD17B10CYP1A2
Hydrochloric Acid SCHEMBL4410239 0.83 ITGB3 (0.53) KDM4EALDH1A1HPGDHSD17B10CYP1A2
SCHEMBL13174376 0.83 HRH3 (0.59) KDM4EALDH1A1HPGDHSD17B10CYP1A2
SCHEMBL31722181 0.79 KDM4E (0.47) KDM4EALDH1A1HPGDHSD17B10CYP1A2
SCHEMBL19885961 0.79 KDM4E (0.60) KDM4EALDH1A1HPGDHSD17B10CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2005118584-A2 SAFRAMYCIN ANALOGS AS THERAPEUTIC AGENTS IN THE TREATMENT OF CANCER AXYS PHARMACEUTICALS, INC. (US) 2005-12-15 WO disclosed